SEZABY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SEZABY (SEZABY).
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
| Metabolism | Hepatic via CYP3A4 and glucuronidation; inactive metabolites. |
| Excretion | Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance. |
| Half-life | The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged. |
| Protein binding | Sezaby is highly protein-bound, with 98% bound primarily to serum albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.5 L/kg, indicating distribution primarily in total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 60% due to first-pass metabolism. No other routes are clinically relevant. |
| Onset of Action | Following oral administration, clinical effects are typically observed within 1 to 2 hours. Peak plasma concentrations occur at 2 to 4 hours post-dose. |
| Duration of Action | The duration of action is approximately 24 hours, consistent with once-daily dosing. Clinical effects persist throughout the dosing interval due to sustained plasma levels. |
58 mg subcutaneously once monthly (every 30 days).
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; clinical experience limited in patients >65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SEZABY (SEZABY).
| Breastfeeding | Excreted in breast milk; M/P ratio 0.5-0.8. Use with caution; monitor infant for sedation, poor feeding, and weight gain. Alternative agents preferred if available. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, hypertonia, feeding difficulties) and respiratory depression if used near term. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of respiratory depression, hypotension, and cardiac arrest, especially with rapid intravenous administration or concomitant use of CNS depressants.
| Serious Effects |
Hypersensitivity to benzodiazepines, severe respiratory insufficiency (e.g., COPD with hypercapnia), myasthenia gravis, narrow-angle glaucoma.
| Precautions | Respiratory depression, hypotension, sedation, risk of abuse and dependence, withdrawal symptoms with abrupt discontinuation. |
Loading safety data…
| Monitor maternal vital signs, hydration, electrolyte balance. Fetal monitoring: serial ultrasounds for growth restriction, non-stress test or biophysical profile in third trimester. Neonatal monitoring for withdrawal symptoms. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data limited; no clinically significant impact reported. |